A new Mayo Clinic-led study suggests that menopausal hormone therapy may give tirzepatide an extra boost in postmenopausal women with overweight or obesity. In this observational analysis, women using both treatments lost about 35% more weight on average than women taking tirzepatide alone.
The findings matter because menopause is often linked with weight gain, shifts in body composition, and a higher risk of cardiometabolic disease. As estrogen levels decline, many women also face greater odds of developing type 2 diabetes and cardiovascular complications.
The research team reviewed outcomes from 120 adults who had taken tirzepatide for at least 12 months and compared people who were also using menopausal hormone therapy with those who were not. The two groups were designed to be similar at baseline, but the study was not randomized, so it cannot prove that hormone therapy directly caused the additional weight loss.
Even so, the signal was strong enough to draw attention. Researchers noted that the result fits with earlier hints from GLP-1-based medicines such as semaglutide, where hormone therapy has also been associated with greater weight loss in some studies. One possible explanation is that estrogen may help enhance appetite suppression or otherwise support metabolic responses to these drugs.
The authors also pointed out another possibility: women using hormone therapy may have had better sleep, fewer menopausal symptoms, or stronger adherence to diet and activity changes, all of which could improve weight-loss outcomes.
For now, the study should be viewed as an early step rather than a treatment recommendation. The next phase will require randomized clinical trials to test whether the combination truly outperforms tirzepatide alone and whether any added benefit extends beyond weight loss to blood sugar, lipids, and other cardiometabolic measures.
If confirmed, this line of research could help shape more personalized obesity treatment strategies for millions of women after menopause.
